United States Pivotal Trial Begins of MicroVention's FRED Stent for Cerebral Aneurysm Flow Diversion
July 22, 2013—MicroVention, Inc. (Tustin, CA), a wholly owned subsidiary of Terumo Corporation (Tokyo, Japan), announced initiation of enrollment in a multicenter, prospective, pivotal clinical trial in the United States to demonstrate the safety and efficacy of the company's flow diversion system called FRED (flow-redirection endoluminal device), for treating intracranial aneurysms.